Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Amphista: broadening the target space of protein degradation

Amphista raised $7.5M to test its targeted protein degradation platform in vivo

By Danielle Golovin, Staff Writer
August 22, 2020 12:49 AM UTC

Amphista aims to apply protein degradation to a broader set of targets and indications using an approach that does not depend on E3 ubiquitin ligases.

The Glasglow-based company spun out of the University of Dundee, where Founder and Director Alessio Ciulli serves as chair of chemical and structural biology...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Advent Life Sciences

Amphista Therapeutics Ltd.

Arvinas Inc.

BioMotiv

European Investment Fund

Glaxosmithkline plc

Kymera Therapeutics Inc.

BCIQ Target Profiles

E3 ubiquitin ligase